About
Biosimilars
Areas of Focus
Categories
Biosimilars
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
182
By Phase
PHASE3: 1PHASE4: 2PHASE1: 1
By Status
COMPLETED: 2TERMINATED: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2023
2024
2025
2026
2027
Today
Hover over trial bars to see details
Recent Trials
NCT06643117Lead Sponsor
Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)
PHASE3Terminated
25 participants
Started: Oct 3, 2024 · Completed: May 13, 2025
NCT06708637Lead Sponsor
Ocular Safety and Usability Study for FYB203 PFS
PHASE4Completed
30 participants
Started: Sep 20, 2024 · Completed: Oct 8, 2024
NCT06551064Lead Sponsor
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients
PHASE1Active, not recruiting
96 participants
Started: Jul 1, 2024 · Completed: Jun 30, 2026
NCT06708624Lead Sponsor
Ocular Safety and Usability Study for FYB201 PFS
PHASE4Completed
31 participants
Started: Jun 11, 2024 · Completed: Aug 8, 2024
Locations (1)
Headquarters
Martinsried, Germany
Map
Loading map...